Table 1.

Patient demographics and baseline characteristics.

	No. of Patients	IV	SQ
Total number of patients treated	21	9	12
Sex
Male	10 (48)	5 (56)	5 (42)
Female	11 (52)	4 (44)	7 (58)
Age years	63 (53-80)	62 (57-79)	64 (53-80)
iNHL Diagnosis
FL	16 (76)	6 (67)	10 (83)
MZL	4 (19)	2 (22)	2 (17)
SLL	1 (5))	1 (11)	0 (0)
FLIPI risk (FL patients)	N=16	N=6	N=10
low	1 (6)	0 (0)	1 (10)
Int	8 (50)	2 (33)	6 (60)
High	7 (44)	4 (67)	3 (30)
Ann Arbor stage
I	1 (5)	0 (0)	1 (8)
II	3 (14)	2 (22)	1 (8)
II	7 (33)	3 (33)	4 (33)
IV	10 (48)	4 (44)	6 (50)
Time since last treatment to N803	25 (1-134)	20 (1-88)	38 (1-134)
Median (range),months
Time since last anti-CD20 to N803	27 (1-134)	22 (2-88)	52 (2-134)
Median (range), months
Anti-CD20 status
Sensitive	16 (76)	7 (78)	9 (75)
Refractory	5 (24)	2 (22)	3 (25)
Number of prior treatments	2 (1-7)	2 (1-7)	2 (1-7)
Median (range), n
Prior Therapies
Chemotherapy combination	17 (81)	8 (89)	9 (75)
Anti-CD20 monotherapy	4 (19)	1 (11)	3 (25)
Lenalidomide	1 (5)	1 (11)	0 (0)
PI3K inhibitor	2 (10)	1 (11)	1 (8)
BTK inhibitor	2 (10)	2 (22)	0 (0)
Radioimmunoconjugate	1 (5)	0 (0)	1 (8)
Auto SCT	1 (5)	1 (11)	0 (0)
Number of prior anti-CD20 treatments Median (range), n	2 (1-4)